Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

June 5, 2019

Primary Completion Date

December 5, 2026

Study Completion Date

December 5, 2026

Conditions
Rectal CancerAdvanced Cancer
Interventions
DRUG

Chemotherapy

"Arm A : Experimental~* Intervention Type : Drug~* Intervention Name : Modified FOLFIRINOX (experimental arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."

DRUG

Radiochemotherapy

"Arm B: Active comparator~* Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor."

Trial Locations (1)

94275

RECRUITING

BENOIST, Le Kremlin-Bicêtre

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03875781 - Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer | Biotech Hunter | Biotech Hunter